secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097561
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences reports FY2025 net loss of $39M; BLA for TA-ERT on track for Q4 2026
--------------------------------------------------------------------------------

- Net loss $39.0M for 2025 vs $53.0M in 2024; R&D expenses fell to $19.5M on cessation of CAH program.
- Cash and equivalents $48.9M at Dec 31, 2025, plus $15M drawn from Avenue Capital loan; runway into early 2027.
- BLA submission for TA-ERT (MPS IIIB) expected Q4 2026 after positive FDA Type B meetings on surrogate endpoint.
- Appointed Dale Hooks as CCO; secured up to $50M growth capital from Avenue Capital with initial $15M funded in Jan 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526097561/0001193125-26-097561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526097561/sprb-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer